Anti-CD19 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD19 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY